Maximizing response to erythropoietin in treating HIV-associated anemia

Cleveland Clinic Journal of Medicine

Volumn 68, Issue 7, 2001, Pages 643-648

  Ifudu, Onyekachi ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; IRON; RECOMBINANT ERYTHROPOIETIN; ZIDOVUDINE;

ANEMIA; BLEEDING; BLOOD TRANSFUSION; DISEASE SEVERITY; DRUG RESPONSE; DYSERYTHROPOIESIS; HEMOLYSIS; HIGH RISK POPULATION; HORMONE BLOOD LEVEL; HORMONE DEFICIENCY; HORMONE RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGONADISM; INFECTION; IRON DEFICIENCY; IRON THERAPY; KIDNEY FAILURE; LABORATORY TEST; NUTRITIONAL DEFICIENCY; PATHOGENESIS; PREVALENCE; REVIEW; WASTING SYNDROME;

EID: 0034944307     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.68.7.643     Document Type: Review

References (55)

1. Sullivan PS, Hanson DL, Chu SY, et al. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV surveillance project. Blood 1998; 91:301-308.
2. Moore RD, Keruly JC, Chaisson RE. Anemia and survival in HIV infection. J AIDS Hum Retrovirol 1998; 19:29-33.
3. Mocroft A, Kirk O, Barton SE, et al for the EuroSIDA study group. Anemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. AIDS 1999; 13:943-950.
4. Zon LI, Arkin C, Groopman JE. Hematologic manifestations of the human immunodeficiency virus. Br J Haematol 1987; 66:251-256.
5. Revicki DA, Brown DE, Henry DH. Recombinant human erythropoietin and health related quality of life of AIDS patients with anemia. J AIDS Hum Retrovirol 1994; 7:474-484.
6. Henry DH, Beall GN, Benson CA, et al. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials Ann Intern Med 1992; 117:739-748.
7. Popovsky MA, Benson K, Glassman AB, et al. Transfusion practices in human immunodeficiency virus-infected patients. Transfusion 1995; 35:612-616.
8. Mir N, Costello C, Luckit J, Lindley R. HIV disease and bone marrow changes: a study of 60 cases. Eur J Haematol 1989; 42:339-343.
9. Mitsuyasu RT. Hematopoietic growth hormones in HIV. In: Volberding P, Jacobson MA, editors. AIDS Clinical Review 1993/1994. New York: Marcel Dekker; 1994:191-213.
10. Macdougall IC, Allen D, Tucker B, et al. Serum interleukin-6 levels are a useful indicator of marrow suppression in patients with resistance to erythropoietin due to inflammatory disease [abstract]. J Am Soc Nephrol 1993; 4:428.
11. Scadden DT, Zeira M, Woon A, et al. Human immunodeficiency virus infection of human bone marrow stromal fibroblasts. Blood 1990; 76:317-322.
12. Schwartz BN, Kessler SW, Rothwell SW, et al. Inhibitory effects of HIV-1 infected stromal cell layers on the production of myeloid progenitor cells in human long-term bone marrow cultures. Exp Hematol 1994; 22:1288-1296.
13. Moses AU, Williams S, Henevild ML, et al. Human immunodeficiency virus infection of bone marrow endothelium reduces induction of stromal hematopoietic growth factors. Blood 1996; 87:919-925.
14. Donahue RE, Johnson MM, Zori LI, et al. Suppression of in vitro hematopoiesis following human immunodeficiency virus infection Nature 1987; 326:200-203.
15. Cleveland RP, Liu YC. CD4 expression by erythroid precursor cells in human bone marrow. Blood 1996, 87:2275-2282.
16. Folks TM, Kessler SW, Orenstein JM, et al. Infection and replication of HIV-1 in purified progenitor cells of normal human marrow. Science 1988; 242:919-922.
17. Stanley SK, Kessler SW, Justement JS, et al. CD34 positive bone marrow cells are infected with HIV in a subset of seropositive individuals J Immunol 1992; 149:689-697.
18. + by human hematopoietic progenitors. Blood 1994; 84:3344-3355.
19. + hematopoietic progenitor cells. Blood 1997; 89:3522-3528.
20. + progenitor cells are not infected by HIV-1 in vivo, but show impaired clonogenesis Br J Haematol 1993; 85:20-24
21. Molina JM, Scadden DT, Sakaguchi M, Fuller B, Woon A, Groopman JE. Lack of evidence for infection of or effect on growth of hematopoietic progenitor cells after in vivo or in vitro exposure to human immunodeficiency virus. Blood 1990; 76:2476-2482.
22. Spivak JL, Barnes DC, Fuchs E, Quinn TC. Serum immunoreactive erythropoietin in HIV-infected patients. JAMA 1989; 261:3104-3107.
23. Kreuzer KA, Rockstroh JK, Jelkmann W, et al. Inadequate erythropoietin response to anemia in HIV patients: relation to serum levels of tumor necrosis factor-alpha, interleukin-6 and their soluble receptors Br J Haematol 1997; 96:235-239.
24. Kotler DP. Human immunodeficiency virus-related wasting: malabsorption syndromes. Semin Oncol 1998; 25:70-75.
25. Stein TP, Nutinsky C, Condoluci D, Schluter MD, Leskiw MJ. Protein and energy substrate metabolism in AIDS patients. Metabolism 1990; 39:876-881.
26. Morfeldt-Manson L, Bottiger B, Nilsson B, et al. Clinical signs and laboratory markers in predicting progression to AIDS in HIV-1 infected patients. Scand J Infect Dis 1991; 23:443-449.
27. Creagh-Kirk T, Doi P, Andrews E, et al. Survival experience among patients with AIDS receiving zidovudine. Follow-up of patients in a compassionate plea program. JAMA 1988; 260:3009-3015.
28. Swanson CE, Tindall B, Cooper DA. Efficacy of zidovudine treatment in homosexual men with AIDS-related complex: factors influencing development of AIDS, survival and drug intolerance. Australian Zidovudine Study Group. AIDS 1994; 8:625-634.
29. Vamvakas E, Kaplan HS. Early transfusion and length of survival in acquired immunodeficiency syndrome: experience with a population receiving medical care at a public hospital. Transfusion 1993; 33:111-118.
30. McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 1993; 43:2245-2252.
31. Abrams DI, Steinhart C, Frascino R. Epoetin alfa therapy for anaemia in HIV-infected patients: impact on quality of life. Int J STD AIDS 2000, 11:659-665.
32. Sloand E, Kumar P, Klein HG, Merritt S, Sacher R. Transfusion of blood components to persons infected with human immunodeficiency virus type 1: relationship to opportunistic infection. Transfusion 1994; 34:48-53.
33. Mudido PM, Georges D, Dorazio D, et al. Human immunodeficiency virus type 1 activation after blood transfusion. Transfusion 1996; 36:860-865.
34. Ifudu O, Matthew JJ, Mayers JD, et al. Severity of acquired immunodeficiency syndrome and the response to erythropoietin in uremia. Am J Kidney Dis 1997; 30:28-35.
35. Shrivastava D, Rao TKS, Sinert R, et al. The efficacy of erythropoietin in human immunodeficiency virus-infected end-stage renal disease patients treated by maintenance hemodialysis. Am J Kidney Dis 1995; 25:904-909.
36. Fischl M, Galpin JE, Levine JD, et al. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 1990; 322:1488-1493
37. Vanholder R, Ringoir S. Infectious morbidity and defects of phagocytic function in end-stage renal disease: a review. J Am Soc Nephrol 1993; 3:1541-1554.
38. Rubin RB, Barton AL, Banner BF, et al. Iron and chronic viral hepatitis: emerging evidence for an important interaction. Dig Dis 1995; 13:223-238.
39. Collins A, Ebben J, Ma J. Frequent intravenous iron dosing is associated with higher infectious deaths [abstract]. J Am Soc Nephrol 1997; 8:190A.
40. Douvas GS, May MH, Crowle AJ. Transferrin, iron, and serum lipids enhance or inhibit Mycobacterium avium replication in human macrophages J Infect Dis 1993; 167:857-864.
41. Barry DM, Reeve AW. Increased incidence of gram-negative neonatal sepsis with intramuscular iron administration. Pediatrics 1977; 60:908-912.
42. Webster MH, Waitkins SA, Stott A. Impaired bacteriological responses in babies after maternal iron dextran infusion. J Clin Pathol 1981; 34:651-654.
43. Knight CD, Klasing KC, Forsyth DM. E. coli growth in serum of iron dextran-supplement pigs. J Anim Sci 1983, 57:387-395.
44. el-Reshaid K, Johny KV, Hakim A, et al. Erythropoietin treatment in haemodialysis patients with iron overload. Acta Haematol 1994; 91:130-135.
45. Fleming LW, Hopwood D, Shepherd AN, et al. Hepatic iron in dialyzed patients given intravenous iron dextran. J Clin Pathol 1990; 43:119-124.
46. Burkes RL, Cohen H, Krailo M, et al. Low serum cobalamin levels occur frequently in the acquired immunodeficiency syndrome and related disorders. Eur J Haematol 1987; 38:141-147.
47. Mueller BU, Jacobsen F, Jaronski P, Lewis LL, Pizzo PA. Erythropoietin for zidovudine-associated anemia in children with HIV infection. Pediatric AIDS And HIV Infection: Fetus to Adolescent 1994; 5:169-173.
48. DaCosta NA, Hultin MB. Effective therapy of human immunodeficiency virus-associated anemia with recombinant human erythropoietin despite high endogenous erythropoietin. Am J Hematol 1991; 36:71-72.
49. Ifudu O, Fowler A. Hepatitis B virus infection and the response to erythropoietin in end-stage renal disease. ASAIO J. In press 2001.
50. Ifudu O, Friedman EA. Effect of increased hemodialysis dose on endogenous erythropoietin production in end-stage renal disease. Nephron 1998; 79:50-54.
51. Gardener TD, Flanagan P, Dryden MS, et al. Disseminated mycobacterium avium-intracellulare (MAI) infection and red cell hypoplasia in patients with acquired immune deficiency syndrome. J Infect 1988; 16:135-140.
52. Ifudu O, Valcourt JS. Does uremia potentiate bacteremia-associated hemolysis in patients receiving erythropoietin? Nephrol Dial Transplant 1999; 14:517-519.
53. Winston JA, Klotman PE. Are we missing an epidemic of HIV-associated nephropathy? J Am Soc Nephrol 1996; 7:1-7
54. Rao TKS, Filippone FJ, Nicastri AD, et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 1984; 310:669-673.
55. Rao TKS, Friedman EA, Nicastri AD. The types of renal disease in the acquired immunodeficiency syndrome. N Engl Med 1987, 316:1062-1068.